← boardnext 2028-11-01
BCLI
Brainstorm-Cell Therapeuticsdistress 8/10 · high distress / dilution risk$1.13+15%today-22% from 52w high
Lead: Amyotrophic Lateral Sclerosis (ALS)
Revenue
pre-revenue
Liquidity
$0M
Runway
0.0 yrs
Shares 1y
+6%
Price & events
+91.5% over 6M
CatalystRating changeDilutionFinancingdashed = today
+15.3%
1D
+20.2%
1W
+24.2%
1M
+44.9%
3M
+88.3%
6M
+63.8%
1Y
-77.8%
2Y
-97.8%
5Y
-98.3%
All
Overview
- Market Cap
- $12.47M
- Volume
- 649
- 52 Week Range
- $0.48 – $1.44
- Total Shares
- 11.03M
- Float Shares
- 9.92M
- Short %
- 6.46%
- % Held by Insiders
- 10.27%
- % Held by Institutions
- 0.00%
- RVOL
- 0.03x
- Beta
- 0.22
Pipeline stages · 1 programs
Debamestrocel - MSC-NTF (NurOwn)
Preclin›
Ph1›
Ph2›
Ph3›
Filed›
PDUFA›
Approved
Pipeline · 1 trials · 1 upcoming
| Readout | Phase | Drug | Indication | Enroll | Status |
|---|---|---|---|---|---|
| 2028-11-01 Estimated 50% readout ~2029-01-15 | Phase 3 | Debamestrocel - MSC-NTF (NurOwn)orphan | Amyotrophic Lateral Sclerosis (ALS), Amyotrophic Lateral Sclerosis | — | not yet recruiting |
Catalyst news & presentations · 2
- 2025-05-19trial initiationsecondaryPhase 3NurOwn · FDA clearance received to initiate Phase 3b clinical trialSEC 8-K
- December 2024enrollment completesecondaryPhase 3NurOwn® · First patient enrollment expected.SEC 8-K
Approved drugs (0)
- none — clinical-stage
Capital structure — dilution & financing
🔒 Top holders — Pro
Institutional ownership + quarter-over-quarter accumulation/trimming.
Upgrade to ProWall St ratings
no consensus
- 2024-07-11Maxim GroupHold → Buy
Competitors — Amyotrophic Lateral Sclerosis (ALS)
- none identified
Recent news
- 2026-07-09Price to earnings forward of BrainStorm Cell Therapeutics Inc. – OTC:BCLI - TradingView
- 2026-06-19Brainstorm Cell Therapeutics Inc (BCLI) Institutional Confidence - TradingKey
- 2026-06-02BrainStorm Cell Therapeutics Announces Publication Calling for Updated FDA Approaches to ALS, Rare Diseases and Regenerative Medicine - PR Newswire
- 2026-05-28BrainStorm Cell Therapeutics Appoints Former FDA Associate Commissioner Peter J. Pitts to Board of Directors - PR Newswire
- 2026-05-15BrainStorm Cell Therapeutics Announces First Quarter 2026 Financial Results and Provides Corporate Update - PR Newswire
- 2026-03-31BrainStorm Cell Therapeutics Announces Full Year 2025 Financial Results and Provides Corporate Update - PR Newswire
- 2026-02-20Brainstorm Cell Therapeutics Announces $1 Million Strategic Financing at Premium to Market - PR Newswire
Not financial advice. Data: ClinicalTrials.gov, SEC EDGAR, FINRA, Nasdaq, Yahoo.